Inozyme Pharma to Participate at the BofA Securities Biotech SMID Cap Conference

Rhea-AI Summary

Inozyme Pharma, a clinical-stage biopharmaceutical company focused on rare diseases, has announced that CEO Axel Bolte will participate in a fireside chat at the BofA Securities Biotech SMID Cap Conference on December 8, 2022, from 8:00-8:30am ET. The event will showcase insights into the company’s work on novel therapeutics, particularly INZ701, a potential first-in-class enzyme therapy for pathologic mineralization and intimal proliferation.
A replay will be available on their website after the event.

BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will participate in a fireside chat at the BofA Securities Biotech SMID Cap Conference on Thursday, December 8, 2022, from 8:00-8:30am ET.

A replay of the fireside chat can be accessed from the Investor Relations section of Inozyme’s website under events and will be available for a limited time following the event.

About Inozyme Pharma

Inozyme Pharma, Inc. (Nasdaq: INZY) is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. We are developing INZ701, a potential first-in-class enzyme therapy, to address pathologic mineralization and intimal proliferation which can drive morbidity and mortality in these severe diseases. INZ-701 is currently in Phase 1/2 clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency.

For more information, please visit www.inozyme.com and follow us on LinkedIn, Twitter, and Facebook.

Contacts

Investors:
Inozyme Pharma
Stefan Riley, Director of IR and Corporate Communications
(857) 330-8871
stefan.riley@inozyme.com

Media:
SmithSolve
Matt Pera
(973) 886-9150
matt.pera@smithsolve.com

FAQ

What date will INZY participate in the BofA Securities Biotech SMID Cap Conference?

Inozyme Pharma (INZY) will participate in the BofA Securities Biotech SMID Cap Conference on December 8, 2022.

Who is representing Inozyme Pharma at the upcoming conference?

CEO Axel Bolte will represent Inozyme Pharma at the conference.

What is INZ701 being developed for by Inozyme Pharma?

INZ701 is being developed as a potential first-in-class enzyme therapy for pathologic mineralization and intimal proliferation.

Where can I access the replay of the Inozyme Pharma conference chat?

The replay will be available on the Investor Relations section of Inozyme Pharma's website.